The effect of dapagliflozin treatment on epicardial adipose tissue volume

Abstract

Treatment with dapagliflozin might improve systemic metabolic parameters and decrease the EAT volume in diabetes mellitus patients, possibly contributing to risk reduction in cardiovascular events.